RT Journal Article
SR Electronic
T1 Hepatitis E in Kathmandu Valley: Insights from a Representative Longitudinal Serosurvey
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.28.23299131
DO 10.1101/2023.11.28.23299131
A1 Katuwal, Nishan
A1 Thapa, Melina
A1 Shrestha, Sony
A1 Vaidya, Krista
A1 Bogoch, Isaac I
A1 Andrews, Jason
A1 Shrestha, Rajeev
A1 Tamrakar, Dipesh
A1 Aiemjoy, Kristen
YR 2023
UL http://medrxiv.org/content/early/2023/11/29/2023.11.28.23299131.abstract
AB Hepatitis-E virus (HEV), an etiologic agent of acute inflammatory liver disease, is a significant cause of morbidity and mortality in South Asia. HEV is considered endemic in Nepal; but data on population-level infection transmission is sparse. We conducted a representative longitudinal serologic study between February 2019 and April 2021 in urban and peri-urban areas of central Nepal to characterize community-level HEV transmission. Individuals were followed up to four times, during which capillary blood samples were collected on dried blood spots and tested for anti-HEV immunoglobulin-G antibodies. Analyzing 2513 dried blood samples from 923 participants aged 0-25 years, we found a seroprevalence of 4.8% and a seroincidence rate of 10.9 per 1000 person-years. Notably, young adults, including women of childbearing age, faced the highest incidence of infection. Geospatial analysis identified potential HEV clusters in Kavre and Kathmandu districts, emphasizing the need for targeted interventions. Water source played a crucial role in HEV transmission, with individuals consuming surface water facing the highest risk of seroconversion. Our findings underscore the endemic nature of HEV in Nepal, emphasizing the importance of safe water practices and potential vaccination strategies for high-risk groups.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the Nepal Health Research Council and Ethics Review Board of Dhulikhel Hospital and Stanford University.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.